Mvabea | European Medicines Agency (EMA)

[ad_1]

Overview

Mvabea is a vaccine to protect adults and children aged one year and older against Ebola virus disease caused by Zaire ebolavirus. It is used with another Ebola vaccine called Zabdeno as part of a vaccine regimen.

Mvabea contains a virus known as Vaccinia Ankara Bavarian Nordic which has been modified to produce 4 proteins from Zaire ebolavirus and three other viruses of the same group (filoviridae). The modified vaccinia Ankara Bavarian Nordic virus itself has no effect on humans. Mvabea only contains parts of the viruses and cannot cause Ebola virus disease.

Mvabea can only be obtained with a prescription and is given by a trained healthcare worker. It is given as a single injection about 8 weeks after an injection of Zabdeno. People who are at imminent risk of infection with Ebola virus and have received the Zabdeno and Mvabea injections more than 4 months earlier can receive a booster dose of Zabdeno.

Injections are given into the muscle around the shoulder (the deltoid) or a muscle of the thigh.

For more information about using Mvabea, see the package leaflet or contact your doctor or pharmacist.

The active substance in Mvabea, when injected in the body, produces 4 viral proteins characteristic of filoviridae, the group of viruses that includes Zaire ebolavirus. When a person receives the vaccine regimen, the viral proteins trigger an immune response. If later on the person comes into contact with Zaire ebolavirus, the immune system recognises the viral proteins and is prepared to attack the virus, so protecting the person from the disease caused by Ebola virus.

Five main studies showed that Mvabea, when used with Zabdeno, can trigger the production of antibodies capable of providing protection against Zaire ebolavirus. The studies involved a total of 3,585 adults and children. Based on animal studies with a fully lethal dose of the virus, the antibody level generated in humans following vaccination with Zabdeno and Mvabea would be expected to lead to around 53% survival if infected with a fully lethal dose. However, the method used in the animal studies results in more severe infection than natural infection in humans. Although the vaccine regimen can provide protection against Ebola virus disease, the level and duration of protection are not yet known and the company will provide further data.

The most common side effects in adults with Mvabea (which may affect more than 1 in 10 people) are pain, warmth and swelling at the injection site, tiredness, muscle pain and joint pain.

In children and adolescents aged 1 to 17 years, the most common side effects (which may affect more than 1 in 10 people) are pain at the injection site and tiredness.

For the full list of side effects and restrictions of Mvabea, see the package leaflet.

Mvabea, used with Zabdeno as part of a 2-dose vaccine regimen, triggers an immune response that can provide protection against Ebola virus disease. Although the level and duration of protection against the virus have not yet been determined, the European Medicines Agency considered that the vaccine’s benefits could be of great importance to help control an outbreak and prevent death. Regarding safety, most side effects are mild to moderate in severity and of short duration. The Agency therefore decided that Mvabea’s benefits are greater than its risks and it can be authorised for use in the EU.

Mvabea has been authorised under ‘exceptional circumstances’. This is because it has not been possible to obtain complete information about Mvabea for scientific and ethical reasons. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.

Since Mvabea has been authorised under exceptional circumstances, the company that markets Mvabea will provide an update on the collection of data on the effectiveness of the vaccine regimen in the intended population on a yearly basis.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mvabea have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Mvabea are continuously monitored. Side effects reported with Mvabea are carefully evaluated and any necessary action taken to protect patients.

Mvabea received a marketing authorisation under exceptional circumstances valid throughout the EU on 01 July 2020.

English (EN)
(137.22 KB – PDF)

First published: 23/07/2020

View

English (EN)
(662.15 KB – PDF)

First published: 23/07/2020Last updated: 25/03/2025

View

Product information

English (EN)
(375.04 KB – PDF)

First published: 23/07/2020Last updated: 07/04/2025

View

Latest procedure affecting product information:
R/0023

26/03/2025

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(42.88 KB – PDF)

First published: 23/07/2020

View

Product details

Name of medicine: Mvabea
Active substance: Recombinant Modified Vaccinia Ankara Bavarian Nordic Virus encoding the: Ebola virus Zaire (ZEBOV) Mayinga strain glycoprotein (GP); Ebola virus Sudan Gulu strain GP; Ebola virus Taï Forest strain nucleoprotein and the Marburg virus Musoke strain GP
International non-proprietary name (INN) or common name: Ebola vaccine (MVA-BN-Filo [recombinant])
Therapeutic area (MeSH): Hemorrhagic Fever, Ebola
Anatomical therapeutic chemical (ATC) code: J07BX

Pharmacotherapeutic group

Vaccines

Therapeutic indication

Active immunization for prevention of disease caused by Ebola virus (Zaire Ebolavirus species) in individuals ? 1 year of age.

[ad_2]

Source link

Mvabea | European Medicines Agency (EMA)

Overview

Product information

Product details

Pharmacotherapeutic group

Therapeutic indication

LEAVE A REPLY Cancel reply

Supreme Court Overturns Block on Trump Administration’s Venezuelan Deportations

How low can the Bitcoin price go?

US having direct talks with Iran over its nuclear programme | US News

User-Friendly Sensitive Toothbrushes : oral b io2

Sei Investments Co. Sells 384,272 Shares of SLM Co. (NASDAQ:SLM)

More Articles Like This

Quick Search

Links

Mvabea | European Medicines Agency (EMA)

Overview

How is Mvabea used?

How does Mvabea work?

What benefits of Mvabea have been shown in studies?

What are the risks associated with Mvabea?

Why is Mvabea authorised in the EU?

What information is still awaited for Mvabea?

What measures are being taken to ensure the safe and effective use of Mvabea?

Other information about Mvabea

Product information

Product details

Pharmacotherapeutic group

Therapeutic indication

LEAVE A REPLY Cancel reply

More Articles Like This

Quick Search

Links